查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980537

mRNA療法市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034年預測

mRNA Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 151 Pages | 商品交期: 請詢問到貨日

價格

mRNA療法市場的成長要素

2025年全球mRNA療法市場規模為60.1億美元。預計到2026年，該市場將成長至68.5億美元，到2034年將進一步擴大至260.6億美元，在預測期（2026-2034年）內，複合年成長率高達18.18%。

預計到2025年，北美將引領全球市場，佔31.47%的市場。這主要得益於強勁的研發投入、有利的監管支持以及基於mRNA的新冠疫苗的早期商業化。

隨著mRNA疫苗在新冠疫情期間取得成功，市場正經歷快速轉型。 Moderna、BioNTech、輝瑞和葛蘭素史克等主要企業正積極拓展其研發管線，將目標領域從感染疾病擴展到癌症和罕見遺傳疾病等領域。

此外，首個 mRNA 藥物（一種非疫苗療法）預計將於 2027 年上市。僅 mRNA 藥物領域預計到 2032 年將達到 20 億美元，並且預計在 2027 年至 2032 年間將以驚人的 118.7% 的複合年成長率成長。

市場動態

市場促進因素

mRNA療法的優勢

與傳統疫苗和治療方法相比，基於mRNA的療法具有多項優勢。這些優勢包括：

  • 在預防重症方面具有很高的有效性
  • 縮短開發週期
  • 對新病毒株的適應力
  • 安全性能良好
  • 整合到基因組的風險較低

新冠肺炎疫情期間展現出的快速反應能力顯著增強了人們對mRNA技術的信心。其在感染疾病、腫瘤和罕見疾病等領域的應用不斷拓展，持續推動市場成長。

市場限制因素

與保存和穩定性相關的挑戰

儘管市場需求依然強勁，但mRNA療法需要超低溫儲存，這給物流帶來了挑戰。在許多資源匱乏的國家，缺乏完善的低溫運輸基礎設施，限制了其供應。

高昂的製造成本

大規模生產mRNA產品需要複雜的純化製程和先進的脂質奈米顆粒（LNP）遞送系統。這些因素顯著增加了生產成本，並限制了生產的規模化。

市場機遇

藥物傳輸技術的進步

遞送系統的持續創新正在提高mRNA的穩定性和治療效果。此類技術的例子包括：

  • 脂質奈米顆粒（LNPs）
  • 聚合物奈米粒子
  • 陽離子奈米粒子

這些技術提高了藥物遞送至細胞的效率。預計這些進展將促進下一代mRNA療法的商業化，尤其是在腫瘤學和罕見疾病領域。

市場挑戰

  • 無論哪個地區，都應採用嚴格的法規結構。
  • 核准流程的變更
  • 公眾輿論和對疫苗接種的猶豫
  • 開發中國家的基礎建設限制

應對這些挑戰對於實現永續的長期成長至關重要。

市場趨勢

超越疫苗：廣泛採用

儘管疫苗仍佔市場主導地位，但mRNA技術正擴大應用於個人化癌症治療和罕見遺傳疾病的治療。目前，約40%的mRNA臨床試驗處於I期，顯示該領域的研發管線正在迅速擴展。

製藥公司正在大力投資以 mRNA 為基礎的癌症治療療法，這凸顯了該技術革新精準醫療的潛力。

細分分析

依類型

市場區隔依以下步驟進行：

1. 用於預防（疫苗）

2. 製藥

2024年，預防醫學領域佔市場主導地位，預計將維持主導地位至2026年。事實上，由於目前已通過核准的mRNA產品僅存在於疫苗類別（COVID-19疫苗和RSV疫苗），預計到2026年，該領域將佔100%的市場佔有率。

然而，從 2027 年開始，受癌症治療和罕見疾病藥物研發管線的推動，製藥業預計將呈現最高的成長率。

透過使用

  • 感染疾病（預計到 2024 年將佔最大佔有率，到 2026 年將佔 100%）
  • 腫瘤學（成長最快的領域）
  • 其他

截至 2025 年 1 月，監管部門僅對感染疾病應用核准，這進一步凸顯了該領域的優越性。

透過分銷管道

  • 醫院藥局（預計到2024年將佔最大市場佔有率）
  • 藥局和零售藥房
  • 其他

由於特殊的管理要求，醫院藥房佔了最大的市場佔有率。預計到2026年，醫院和零售藥局的市佔率將達到63.62%。

區域展望

北美洲

預計北美將引領全球市場，到 2025 年市場規模將達到 18.9 億美元。美國仍然是主要貢獻者，這得益於聯邦政府的大力資助和 FDA 的核准，預計到 2026 年市場規模將達到 21.6 億美元。

歐洲

預計歐洲市場將出現顯著成長。德國市場預計到2026年將達到3.7億美元，而英國市場預計到2026年將達到1.5億美元。

亞太地區

預計亞太地區將呈現最高的成長率。到2026年：

  • 日本：6.3億美元
  • 中國：5.8億美元
  • 印度：2.7億美元

加大研發投入正在推動該地區的擴張。

世界其他地區

儘管拉丁美洲、中東和非洲在 2024 年的市場佔有率較小，但隨著醫療基礎設施的改善，這些地區的市場佔有率預計將穩步成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 概述：mRNA技術的進展
  • mRNA療法的未來成長前景
  • 主要企業管道分析
  • 併購、收購和合作等主要產業趨勢
  • 關稅對市場的影響

第5章：2021-2034年全球mRNA治療藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：依類型
    • 預防醫學（疫苗）
      • 2019冠狀病毒病疫苗
      • 非新冠疫苗
    • 製藥
  • 市場分析、洞察與預測：依應用領域分類
    • 腫瘤學
    • 感染疾病
    • 其他
  • 市場分析、洞察與預測：依分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 其他
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章：北美mRNA治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲mRNA治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第8章：亞太地區mRNA治療藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：全球其他地區mRNA治療藥物市場分析、洞察與預測（2021-2034年）

第10章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Moderna Inc.
    • BioNTech
    • Pfizer Inc.
    • CureVac SE
    • GSK plc
    • Sanofi
    • Omega Therapeutics
    • Strand Therapeutics
    • Immunomic Therapeutics
Product Code: FBI113411

Growth Factors of mRNA therapeutics Market

The global mRNA therapeutics market was valued at USD 6.01 billion in 2025. The market is projected to grow to USD 6.85 billion in 2026 and further expand to USD 26.06 billion by 2034, exhibiting a strong CAGR of 18.18% during the forecast period (2026-2034).

North America dominated the global market in 2025, accounting for 31.47% market share, driven by robust R&D investments, favorable regulatory support, and early commercialization of mRNA-based COVID-19 vaccines.

The market has undergone rapid transformation following the success of mRNA vaccines during the COVID-19 pandemic. Leading companies such as Moderna Inc., BioNTech, Pfizer Inc., and GSK plc. are actively expanding their pipelines beyond infectious diseases into oncology and rare genetic disorders.

Additionally, the first mRNA drug (non-vaccine therapeutic) is expected to launch in 2027. The mRNA drugs/medications segment alone is projected to reach USD 2 billion by 2032, growing at an exceptional CAGR of 118.7% between 2027 and 2032.

Market Dynamics

Market Drivers

Advantages of mRNA Therapeutics

mRNA-based therapeutics offer several advantages over conventional vaccines and treatments. These include:

  • High efficacy in preventing severe illness
  • Faster development timelines
  • Adaptability to emerging virus strains
  • Favorable safety profile
  • Lower risk of genomic integration

The rapid response capability demonstrated during the COVID-19 pandemic significantly strengthened confidence in mRNA technology. Growing applications in infectious diseases, oncology, and rare disorders continue to drive market expansion.

Market Restraints

Storage and Stability Challenges

Despite strong demand, mRNA therapeutics require ultra-cold storage conditions, creating logistical challenges. Many low-resource countries lack adequate cold chain infrastructure, limiting widespread adoption.

High Manufacturing Costs

The large-scale production of mRNA products involves complex purification processes and advanced lipid nanoparticle (LNP) delivery systems. These factors significantly increase production costs and limit scalability.

Market Opportunities

Advancements in Drug Delivery Technologies

Ongoing innovations in delivery systems are improving mRNA stability and therapeutic effectiveness. Technologies such as:

  • Lipid nanoparticles (LNPs)
  • Polymeric nanoparticles
  • Cationic nanoparticles

are enhancing intracellular delivery efficiency. These advancements are expected to support commercialization of next-generation mRNA therapies, especially in oncology and rare diseases.

Market Challenges

  • Stringent regulatory frameworks across regions
  • Evolving approval pathways
  • Public perception and vaccine hesitancy
  • Infrastructure limitations in developing economies

Addressing these challenges will be essential for sustained long-term growth.

Market Trends

Growing Adoption Beyond Vaccines

While vaccines dominate the market, mRNA technology is increasingly being used for personalized cancer therapies and rare genetic conditions. Nearly 40% of mRNA clinical trials are currently in Phase I, reflecting a rapidly expanding pipeline.

Pharmaceutical companies are heavily investing in oncology-focused mRNA therapeutics, highlighting the technology's potential to revolutionize precision medicine.

Segmentation Analysis

By Type

The market is segmented into:

1. Prophylactic (Vaccines)

2. Drugs/Medications

The prophylactic segment dominated the market in 2024 and is expected to maintain leadership through 2026. In fact, the segment is projected to account for 100% of the market share in 2026, as approved mRNA products currently exist only in the vaccine category (COVID-19 and RSV vaccines).

However, the drugs/medications segment is projected to grow at the fastest rate post-2027, driven by oncology and rare disease pipelines.

By Application

  • Infectious Diseases (Dominant in 2024 and expected to contribute 100% share in 2026)
  • Oncology (Fastest growing)
  • Others

As of January 2025, regulatory approvals exist only for infectious disease applications, reinforcing this segment's dominance.

By Distribution Channel

  • Hospital Pharmacies (Largest share in 2024)
  • Drug Stores & Retail Pharmacies
  • Others

Hospital pharmacies accounted for the highest share due to professional administration requirements. The hospital & retail pharmacies segment is projected to hold 63.62% market share in 2026.

Regional Outlook

North America

North America generated USD 1.89 billion in 2025 and led the global market. The U.S. remains the dominant contributor and is estimated to reach USD 2.16 billion by 2026, supported by strong federal funding and FDA approvals.

Europe

Europe is projected to witness significant growth. Germany is expected to reach USD 0.37 billion by 2026, while the U.K. market is forecast at USD 0.15 billion in 2026.

Asia Pacific

Asia Pacific is anticipated to grow at the fastest rate. By 2026:

  • Japan: USD 0.63 billion
  • China: USD 0.58 billion
  • India: USD 0.27 billion

Increasing R&D investments are fueling regional expansion.

Rest of the World

Latin America and the Middle East & Africa held smaller shares in 2024 but are expected to grow steadily with improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive with key players including:

  • Moderna Inc.
  • BioNTech
  • Pfizer Inc.
  • CureVac SE
  • GSK plc.
  • Sanofi
  • Omega Therapeutics
  • Strand Therapeutics

These companies focus heavily on R&D, pipeline expansion, and strategic partnerships to strengthen their market presence.

Conclusion

The global mRNA therapeutics market is set for remarkable expansion, increasing from USD 6.01 billion in 2025 to USD 6.85 billion in 2026, and reaching USD 26.06 billion by 2034, growing at a CAGR of 18.18%. North America remains the leading region, supported by strong regulatory backing and innovation ecosystems. While vaccines currently dominate the market, the rapid emergence of mRNA-based drugs for oncology and rare diseases signals the next major growth phase. Overcoming storage, cost, and regulatory challenges will be critical to sustaining this strong upward trajectory through 2034.

Segmentation

By Type

  • Prophylactic (Vaccines)
    • COVID-19 Vaccines
    • Non-COVID-19 Vaccines
  • Drugs/Medications

By Application

  • Oncology
  • Infectious Diseases
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Others

By Region

  • North America (By Type, Application, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Type, Application, Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Advancements in mRNA Technology
  • 4.2. Future Growth Prospects for mRNA Therapeutics
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Impact of Tariff on the Market

5. Global mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Prophylactic (Vaccines)
      • 5.1.1.1. COVID-19 Vaccines
      • 5.1.1.2. Non-COVID-19 Vaccines
    • 5.1.2. Drugs/Medications
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Oncology
    • 5.2.2. Infectious Diseases
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Drug Stores & Retail Pharmacies
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Prophylactic (Vaccines)
      • 6.1.1.1. COVID-19 Vaccines
      • 6.1.1.2. Non-COVID-19 Vaccines
    • 6.1.2. Drugs/Medications
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Oncology
    • 6.2.2. Infectious Diseases
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Drug Stores & Retail Pharmacies
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Prophylactic (Vaccines)
      • 7.1.1.1. COVID-19 Vaccines
      • 7.1.1.2. Non-COVID-19 Vaccines
    • 7.1.2. Drugs/Medications
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Oncology
    • 7.2.2. Infectious Diseases
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Drug Stores & Retail Pharmacies
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Prophylactic (Vaccines)
      • 8.1.1.1. COVID-19 Vaccines
      • 8.1.1.2. Non-COVID-19 Vaccines
    • 8.1.2. Drugs/Medications
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Oncology
    • 8.2.2. Infectious Diseases
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Drug Stores & Retail Pharmacies
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World mRNA Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Prophylactic (Vaccines)
      • 9.1.1.1. COVID-19 Vaccines
      • 9.1.1.2. Non-COVID-19 Vaccines
    • 9.1.2. Drugs/Medications
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Oncology
    • 9.2.2. Infectious Diseases
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Drug Stores & Retail Pharmacies
    • 9.3.3. Others

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Moderna Inc.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. BioNTech
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Pfizer Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. CureVac SE
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. GSK plc
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Sanofi
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Omega Therapeutics
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Strand Therapeutics
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Immunomic Therapeutics
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 3: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 4: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global mRNA Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 8: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 9: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 13: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 14: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 18: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific mRNA Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Prophylactic, 2021-2034
  • Table 23: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 24: Rest of the World mRNA Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global mRNA Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global mRNA Therapeutics Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global mRNA Therapeutics Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global mRNA Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 8: North America mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 10: North America mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America mRNA Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America mRNA Therapeutics Market Value Share (%), By Country, 2025
  • Figure 14: Europe mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 16: Europe mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 18: Europe mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific mRNA Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific mRNA Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Rest of the World mRNA Therapeutics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Rest of the World mRNA Therapeutics Market Value Share (%), by Type, 2025
  • Figure 32: Rest of the World mRNA Therapeutics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Rest of the World mRNA Therapeutics Market Value Share (%), by Application, 2025
  • Figure 34: Rest of the World mRNA Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Rest of the World mRNA Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Global mRNA Therapeutics Market Share (%), By Company, 2025